Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Revance Therapeutics (RVNC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

SCMP : 15.70 (-1.88%)
AGN : 172.26 (+2.66%)
VTGN : 1.17 (-35.00%)
RVNC : 34.30 (-1.01%)
Revance Announces Pricing of Public Offering of Common Stock

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"),...

RVNC : 34.30 (-1.01%)
Revance's Neuromodulator Injection Positive in Phase III

Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.

CORT : 17.23 (+2.62%)
ACHN : 2.94 (+1.38%)
AGN : 172.26 (+2.66%)
RVNC : 34.30 (-1.01%)
Today's Research Reports on Stocks to Watch: Revance Therapeutics and Adamis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 6, 2017 / Shares of Revance headed higher on Tuesday after announcing successful results in a pair of phase 3 clinical trials that are evaluating its RT002 treatment...

ADMP : 4.28 (-6.96%)
RVNC : 34.30 (-1.01%)
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

RARE : 45.99 (+0.92%)
CLVS : 63.75 (+2.57%)
ABBV : 97.24 (+1.34%)
REGN : 380.93 (+0.04%)
AMGN : 177.33 (+1.09%)
BIIB : 326.16 (+0.12%)
RVNC : 34.30 (-1.01%)
Regal Entertainment and Revance rise; Ascena Retail slips

NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:

TOL : 47.62 (-0.52%)
EIX : 72.90 (+1.53%)
RVNC : 34.30 (-1.01%)
RGC : 22.74 (+0.04%)
Revance Announces Proposed Public Offering of Common Stock

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"),...

RVNC : 34.30 (-1.01%)
Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines

--- RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 -

RVNC : 34.30 (-1.01%)
Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its...

RVNC : 34.30 (-1.01%)
Noteworthy Wednesday Option Activity: RVNC, AXTA, SFL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Revance Therapeutics Inc , where a total of 2,728 contracts have traded so far, representing...

RVNC : 34.30 (-1.01%)
Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that the U.S....

RVNC : 34.30 (-1.01%)
Revance Releases Third Quarter 2017 Results

---SAKURA 3 open-label safety study for glabellar lines has completed enrollment of more than 2,100 subjects-

RVNC : 34.30 (-1.01%)
Revance Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Revance Therapeutics, Inc. (NASDAQ: RVNC) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern...

RVNC : 34.30 (-1.01%)
Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will...

RVNC : 34.30 (-1.01%)
Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced it has completed...

RVNC : 34.30 (-1.01%)
Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will...

RVNC : 34.30 (-1.01%)
Revance Appoints Mark Foley to its Board of Directors

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that Mark Foley...

AGN : 172.26 (+2.66%)
RVNC : 34.30 (-1.01%)
Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will...

WFC : 58.70 (-1.03%)
RVNC : 34.30 (-1.01%)
Revance Releases Second Quarter 2017 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced results for...

RVNC : 34.30 (-1.01%)
Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will...

RVNC : 34.30 (-1.01%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL -0.50 , AMP -0.85 , LB +0.23 , AXP +0.27 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.